Дисертації з теми "Carcinoma Endometrio"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 дисертацій для дослідження на тему "Carcinoma Endometrio".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте дисертації для різних дисциплін та оформлюйте правильно вашу бібліографію.
Velasco, Sánchez Ana. "Oncogenes y genes supresores de tumores en carcinoma de endometrio." Doctoral thesis, Universitat de Lleida, 2012. http://hdl.handle.net/10803/110545.
Повний текст джерелаL'objectiu principal d'aquest treball ha estat la identificació d'alteracions moleculars que participin de manera significativa al desenvolupament i la progressió del càncer d'endometri, amb el propòsit d'afegir més claus pel descobriment de noves dianes de diagnosi i teràpies individuals contra aquesta patologia. El treball ha estat centrat en l’estudi de modificacions en l’ADN de les cèl-lules que formen el teixit tumoral en una sèrie de pacients amb carcinoma endometrial, en concret, en l’anàlisi mutacional del gens PIK3CA i FGFR2 i l’anàlisi de hipermetilació del promotor dels gens RASSF1A i SPRY2, elements que formen part d’importants vies de transducció de senyals implicades principalment en processos de creixement i diferenciació cel-lular. En primer lloc hem advertit cert grau de variabilitat en el patró d'expressió dels gens estudiats entre els teixits tumoral i no tumoral i aquestes diferències d'expressió són, en part, degudes a l'existència de hipermetilació en les regions promotores dels gens implicats. Així mateix, la presencia de mutacions en regions gèniques que codifiquen parts de la proteïna claus per la seva funció a la cèl-lula, és també un factor que modifica el patró d'expressió entre entre els teixits tumoral i no tumoral. En concret, després de l’anàlisi immunohistoquímic de l’expressió de RASSF1A i la presència o absència de metilació a la zona promotora del gen RASSF1A, es van detectar tumors amb nivells d’expressió reduïts i presència de hipermetilació en el promotor, ambdós fenòmens associats de manera estadísticament significativa. El mateix passa, encara que amb diferent grau, amb l’expressió de SPRY2 en alguns tumors en associació amb la presència de ipermetilació en el promotor del gen. A través d’aquest anàlisi hem descobert que l’expressió de SPRY2 presenta variabilitat en les glàndules endometrials dels teixits no tumorals al llarg del cicle menstrual. D'altra banda hem vist com el gen PIK3CA es troba freqüentment mutat en les cèl-lules que formen els tumors de carcinoma d'endometri i coincideix amb la presència de mutacions en el gen PTEN. No obstant això, la freqüència de mutacions en el gen FGFR2 s'ha mostrat baixa encara que la seva expressió a nivell inmunohistoquímic reflecteix diferencies entre carcinoma de tipus endometrioide y no endometrioide. Finalment, afegir una revisió d'un dels fenòmens més freqüent en la formació i el progrés dels tumors en carcinoma d'endometri: el concepte de "pèrdua de heterozigositat". En aquest treball hem considerat primordial incloure una obra en que es realitza una incursió als mecanismes moleculars a través dels quals es produeix la pèrdua de heterozigositat, aixi com els mètodes que s'utilitzen en la seva detecció i el significant d'alguns patrons de pèrdua de heterozigositat en determinades regions cromosòmiques en carcinoma d'endometri.
The main point of this study was the identification of molecular alterations that participate in the development and progression of endometrial cancer, in order to add more keys to the discovery of new targets for diagnosis and therapies against this disease. The work has been focused on the study of molecular alterations of DNA from tumour tissues in a series of endometrial carcinoma patients, above all, mutational analysis of PIK3CA and FGFR2 genes and analysis of promoter hyper methylation of SPRY2 and RASSF2A genes, together forming part of signal transduction pathways that are involved in processes of growth and cell differentiation. To begin with, we noticed some variability in the gene expression pattern examined between tumour and normal tissue, and these differences are partly due to hyper methylation in promoter regions at the involved genes. Likewise, mutations in gene regions encoding key protein domains in the cell are also a factor that modifies the gene expression pattern between tumour and normal tissue. In particular, after analysing the immunohistochemical expression of RASSF1A and the presence or absence of methylation in the RASSF1A gene promoter we detected tumours with low expression levels and promoter hyper methylation. The same applies, albeit in a different degree, with SPRY2 expression in some tumours in association with the presence of gene promoter hyper methylation. Through this analysis we found some SPRY2 expression variability in endometrial glands from non-tumour tissues throughout the menstrual cycle. On the other hand we have seen that the PIK3CA gene is frequently mutated in tumour cells from endometrial carcinoma, and this is also a PTEN gene mutation coincident event. However, FGFR2 gene mutation ratio has shown to be low although immunohistochemical expression reflects differences between endometrioid endometrial carcinoma and no-endometrioid type. Finally, we wanted to add a review of one of the phenomena, which occurs more frequently during the formation and progress of tumours in endometrial carcinoma: LOH "loss of heterozygosity". We have considered essential include a review work about the molecular mechanisms through which loss of heterozygosity is produced, the methods used in their detection and significance of some patterns of loss of heterozygosity in specific chromosomal regions in endometrial carcinoma.
Tonon, Ângela Favorito Santarém [UNESP]. "Claudina-3 e Claudina- 4, potenciais marcadores de agressividade no carcinoma endometrial Tipo I." Universidade Estadual Paulista (UNESP), 2013. http://hdl.handle.net/11449/108608.
Повний текст джерелаO Carcinoma de Endométrio é a neoplasia epitelial maligna que acomete mulheres no pré, pós e peri -menopausa. Segundo diferenças endócrinas, metabólicas, fatores de risco e morfologia é classificado em dois grandes grupos: Tipo I (endometrióide) e Tipo II (não endometrióide). O Tipo I perfaz 90 % dos carcinomas de endométrio e sua patogenia esta ligada a exposição excessiva ao estrógeno. O Tipo II é incomum, com fatores predisponentes menos conhecidos. O sintoma mais relevante do carcinoma de endométrio é o sangramento pós-menopausa. Seu diagnóstico é feito pela comprovação histológica, associada aos exames de imagem e laboratoriais. Seu tratamento é fundamentalmente cirúrgico. O fator prognóstico mais importante é a presença ou ausência de metástase nos linfonodos regionais. Atualmente, buscam-se marcadores biológicos e teciduais que indiquem pior prognóstico. Este trabalho verificou a imunoexpressão da claudina-3 (CLDN3) e claudina-4 (CLDN4) nos carcinomas de endométrio Tipo I e Tipo II, relacionando-as com endométrio proliferativo e atrófico, aspectos clínicos, anatomopatológicos, perfil hormonal, índice de proliferação celular e expressão da p53, na tentativa de estabelecer a importância destas proteínas na progressão e agressividade tumoral e o seu valor prognóstico. Foram estudados 79 casos de carcinoma de endométrio e comparados com 74 endométrios normais. Avaliou-se a imunoexpressão das CLDNs 3 e 4, receptor estrogênico, receptor de progesterona, índice de proliferação celular (Ki67) e p53, pela técnica de imunoistoquímica. Observou-se que o padrão de coloração da membrana para CLDN3 se mostrou difuso nos carcinomas, quando comparado com os endométrios normais que exibiu padrão focal. O número de células marcadas com CLDN3 estava diminuído nos carcinomas Tipo I, porém com intensidade aumentada. Nesta análise foi possível verificar que ...
Carcinoma of the Endometrium is a malignant epithelial tumor which affects pre, peri and post-menopausal women. It is classified into two major groups, according to endocrine, metabolic risk factors and morphological differences: Type I (endometrioid) and Type II (non-endometrioid). Type I accounts for 90% of all endometrial carcinomas and its pathogenesis is linked to excessive estrogen exposure. The Type II is less common, with poorly defined predisposing factors. The most important symptom of endometrial carcinoma is postmenopausal bleeding. Diagnosis is achieved through histological evidence, in association with imaging and laboratorial exams. Treatment is primarily surgical. The most important prognostic factor is the presence or absence of metastases in regional lymph nodes. Bio and tissue markers that indicate worse prognosis are the focus of current research. This study examined the immunoexpression of claudin-3 (CLDN3) and claudin-4 (CLDN4) in endometrial carcinomas Type I and Type II, and their relation to proliferative and atrophic endometrium, clinical and pathological features, hormonal status, proliferation index and p53 expression, in an attempt to establish the importance of these proteins in tumor progression and aggressiveness and their prognostic value. Seventy-nine cases of endometrial carcinoma were studied and compared with 74 normal endometria. The immunoexpression of CLDNs 3 and 4, estrogen receptor, progesterone receptor, cell proliferation index (Ki67) and p53 were all evaluated by immunohistochemistry. Observation verified that the pattern of membrane staining for CLDN3 was diffuse in carcinomas compared with normal endometrium which presented a focal pattern. The number of cells stained with CLDN3 was lower in Type I carcinomas, while staining intensity was greater. Analysis verified that 25% of cases with high expression of CLDN4 and Ki-67 developed metastasis, while 33% of cases with greater CLDN4 staining ...
Lombardelli, Karen Vicencia Pingarilho. "Ressonancia magnetica resumida na avaliação da extensão do carcinoma de endometrio." [s.n.], 2008. http://repositorio.unicamp.br/jspui/handle/REPOSIP/310562.
Повний текст джерелаDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas
Made available in DSpace on 2018-08-11T20:18:21Z (GMT). No. of bitstreams: 1 Lombardelli_KarenVicenciaPingarilho_M.pdf: 1393759 bytes, checksum: 03f9bf792d32993984a7a2ab742d670a (MD5) Previous issue date: 2008
Resumo: Introdução: A ressonância magnética (RM) é um exame que pode auxiliar no estadiamento pré-cirúrgico da paciente com carcinoma de endométrio, o que permite planejar mais adequadamente a cirurgia, principalmente quando há evidências de doença avançada e em mulheres com comorbidades clínicas relevantes. Todavia, é um exame demorado, exige cooperação e imobilidade, emite ruído e o espaço físico é restrito, ocasionando desconforto e claustrofobia. Motivos referidos, inclusive como justificativa de interrupção do exame. A mobilidade durante o exame, incluindo movimentos respiratórios acentuados, assim como o alto índice de obesidade em mulheres com carcinoma de endométrio podem gerar artefatos que comprometem a qualidade da imagem, prejudicado o diagnóstico final. Simplificar o exame com redução do tempo de duração sem prejudicar a qualidade do diagnóstico seria muito útil. Objetivos: O objetivo deste estudo foi avaliar se a subtração das seqüências T1 FS sagital e T2 TSE coronal, sem contraste e com aquisições de alta resolução, comprometeria o desempenho diagnóstico na avaliação da extensão do carcinoma de endométrio. Material e Métodos: Este estudo foi observacional e descritivo, de corte transversal. Foram incluídas 62 mulheres com diagnóstico histológico de carcinoma de endométrio. As pacientes fizeram RM da pelve que foi analisada por dois médicos especialistas, sendo que um avaliou o exame completo e o outro o exame resumido, sem troca de informações entre eles. Os achados da RM completa e resumida foram comparados com os laudos anatomopatológicos. Para testar a associação entre as variáveis qualitativas foi utilizado o teste qui-quadrado. A concordância diagnóstica entre os exames completo e resumido da RM foi analisada pelo Coeficiente de Kappa. Resultados: As medianas, médias, desvios-padrão e valores máximos das medidas do maior diâmetro do tumor avaliadas pelas RMC, RMR e patologia foram muito próximas. As medianas, médias, desvios-padrão, valores mínimos e valores máximos do volume do tumor avaliado pelas RMC e RMR foram muito próximos. A mediana do volume do tumor avaliado pela patologia foi muito próxima das medianas obtidas pela ressonância magnética, enquanto que a média, desvio-padrão e valor máximo apresentaram valores maiores. Conclusões: A RMR apresenta desempenho semelhante ao da RMC na avaliação da extensão do carcinoma do endométrio. A concordâncJa observada para avaliação da invasão, miometrial, do colo do útero e dos linfonodos pélvicos foi classificada como muito boa ou excelente. A concordância na avaliação da invasão do colo do útero entre a patologia e as RMC e RMR foi classificada como muito boa (Tabela 2). A concordância observada para avaliação das invasões miometrial e do colo do útero entre os exames de RM foi classificada como muito boa ou excelente. Portanto, é possível utilizar o exame de RM sem as seqüências T1 SE sagital sem contraste e T2 TSE caronal, pois não haverá prejuízo na qualidade do diagnóstico
Abstract: Background: Magnetic resonance imaging (MRI) is an exam that may be helpful in establishing presurgical staging of patients with endometrial carcinoma, allowing a more appropriate surgical procedure to be planned, principally in the case of advanced disease or in women with relevant clinical comorbidities. However, it is a protracted exam that requires cooperation and immobility. In addition, it is noisy and physical space is restricted, often causing discomfort, anxiety and claustrophobia that may lead to interruption of the exam. Movements including accentuated breathing may generate artifacts that compromise the quality of images. Simplifying the exam by reducing the time required to carry it out without affecting the quality of diagnosis would be extremely useful. Objectives: To evaluate whether modification to the routine MRI (complete MRI) by eliminating the non contrast high resolution sagittal T1-weighted FS and caronal T2-weighted TSE sequences (resumed MRI), negatively affects performance of this exam in the diagnosis of the extent of endometrial carcinoma. Methods: A cross sectional, observational, descriptive study was carried out in 62 women with endometrial carcinoma. All underwent pelvic MRI, which was analyzed by two radiologists. Complete and rapid MRI findings were compared with anatomopathology reports. The chi-square test was used to test the association between qualitative variables. Diagnostic agreement between complete and resumed MRI was analyzed using the kappa coefficient. Results: There were no statistically significant differences in the medians, means, standard deviations or maximum values of the measurements of the greatest diameter and of tumor volume as evaluated by complete MRI, resumed MRI and pathology. With respect to myometrial invasion, agreement between complete and resumed MRI was classified as very good, with a kappa coefficient of 0.73 (0.54 - 0.93). Agreement in the evaluation of myometrial invasion between pathology and complete or resumed MRI was classified as good. With respect to cervical invasion, agreement between complete and rapid MRI was classified as excellent, with a kappa coefficient of 0.96 (0.87 - 1.00). Agreement in the evaluation of cervical invasion between pathology and complete and resumed MRI was classified as very good. With respect to pelvic Iymph nodes, agreement between complete and resumed MRI was classified as excellent, with kappa coefficients of 0.93 (0.84 - 1.00) and 0.96 (0.90 - 1.00), respectively. Conclusions: MRI without the non-contrast sagittal T1-weighted SE and coronal T2-weighted TSE sequences maintains the same performance as complete MRI in evaluating the extent of endometrial carcinoma. The shorter time required to carry out the exam would, therefore, be beneficial to the patients, reducing their discomfort and, principally, decreasing reactions of anxiety and claustrophobia. Moreover, costs to healthcare services, and indirectly to the patients, would also be reduced, since the productivity of the equipment and the team would be higher
Mestrado
Ciencias Biomedicas
Mestre em Tocoginecologia
Testoni, Blasco di Sciacca Alessandra Lucia Maria. "Metalloproteasi 9, TIMP-1 e Osteopontina quali possibili biomarcatori del carcinoma dell endometrio." Doctoral thesis, Università di Catania, 2012. http://hdl.handle.net/10761/1217.
Повний текст джерелаCubo, Abert Montserrat. "Estadificación prequirúrgica del carcinoma endometrial mediante ecografía en dos y tres dimensiones." Doctoral thesis, Universitat Autònoma de Barcelona, 2021. http://hdl.handle.net/10803/672056.
Повний текст джерелаObjetivos: Nuestro objetivo fue comparar el rendimiento diagnóstico de la ecografía transvaginal (ETV) y la resonancia magnética (RM) para predecir la profundidad de la invasión del miometrio (IMP) y la invasión del estroma cervical (IEC) en pacientes con cáncer de endometrio (CE). Métodos: Estudio prospectivo y consecutivo que incluye todas las pacientes con CE diagnosticadas entre octubre de 2013 y julio de 2018 en el Hospital Vall d’Hebron de Barcelona. La estadificación preoperatoria se realizó con ETV y RM seguida de estadificación quirúrgica. La histología final se consideró como estándar de referencia. Se calcularon la sensibilidad, la especificidad, las razones de probabilidad y la precisión diagnóstica para ambas técnicas de imagen para la predicción de IMP y IEC. Se calculó el índice de concordancia. Se utilizaron las pautas STARD 2015. Resultados: Se incluyeron un total de 177 pacientes de forma consecutiva. La sensibilidad fue mayor para ETV en comparación con RM tanto para la predicción de IMP (68% (95% CI 55-79) versus 60% (95% CI 47-72), respectivamente) como para la predicción de IEC (49% (95% CI 35- 62) versus 29% (IC 95% 18-43), respectivamente). Las especificidades fueron similares para la predicción de IMP (ETV 84% (95% CI 77-90) y ETV 92% (95% CI 85-96)) e iguales para IEC (95% (95% CI 90-98). El índice de acuerdo entre ETV y RM fue 0,74 para IMP y 0,99 para IEC. Conclusiones: El rendimiento diagnóstico de ETV no es inferior a la RM para la predicción de IMP y la IEC en el carcinoma de endometrio y puede desempeñar un papel como técnica de imagen de primera línea en la evaluación preoperatoria del cáncer de endometrio.
Objectives: We aimed to compare the diagnostic performance of transvaginal ultrasound (TVUS) and magnetic resonance imaging (MRI) to predict the depth of myometrial invasion (DMI) and cervical stromal invasion (CSI) in patients with endometrial cancer (EC). Methods: Prospective and consecutive study including all EC diagnosed between October 2013 and July 2018 at the Vall d’Hebron Hospital in Barcelona. Preoperative staging was performed with TVUS and MRI followed by surgical staging. Final histology was considered as the reference standard. Sensitivity, specificity, likelihood ratios and diagnostic accuracy were calculated for both imaging techniques for the prediction of DMI and CSI. Agreement index was calculated. The STARD 2015 guidelines were used. Results: A total of 177 patients were consecutively included. Sensitivity was higher for TVUS compared to MRI both for the prediction of DMI (68% (95%CI 55-79) versus 60% (95%CI 47-72), respectively) and CSI (49% (95%CI 35-62) versus 29% (95%CI 18-43), respectively). Specificities were similar for the prediction of DMI (TVUS 84% (95%CI 77-90) and MRI 92% (95%CI 85-96)) and equal for CSI (95% (95%CI 90-98). The agreement index between TVUS and MRI was 0.74 for DMI and 0.99 for CSI. Conclusions: The diagnostic performance of TVUS is not inferior to MRI for the prediction of DMI and CSI in EC and can play a role as a first line imaging technique in the preoperative evaluation of endometrial cancer.
Universitat Autònoma de Barcelona. Programa de Doctorat en Pediatria, Obstetrícia i Ginecologia
Sorolla, Bardají Anabel. "Estudi del proteasoma i altres dianes terapèutiques en el melanoma i el carcinoma d’endometri." Doctoral thesis, Universitat de Lleida, 2012. http://hdl.handle.net/10803/83625.
Повний текст джерелаDada la resistencia a la quimioterapia que presenta el melanoma y el carcinoma de endometrio avanzado, es importante aquella investigación destinada a buscar dianas terapéuticas. En este trabajo hemos investigado los efectos de análogos de la somatostatina (SAs), de inhibidores del proteasoma (PI) como Bortezomib, del inhibidor de receptores tirosina cinasa Sunitinib y la combinación de Sunitinib y Bortezomib en líneas celulares de melanoma. Esta combinación también la hemos testado en el carcinoma de endometrio. Se observa que las células de melanoma expresan varios receptores de la somatostatina. Los PI son eficientes a la hora de inducir una parada en el ciclo celular y apoptosis. Las líneas celulares que presentan PDGFR α i VEGFR2 son sensibles a Sunitinib, y éste interacciona con Bortezomib de forma sinérgica. En el carcinoma de endometrio, Sunitinib induce una parada en el ciclo celular, apoptosis, inhibe la via NFκB e interacciona sinérgicamente con Bortezomib. Los SAs y PI podrían ser útiles en combinación con otros agentes y el uso de Bortezomib y Sunitinib ha demostrado ser efectivo en determinados casos de melanoma y en el carcinoma de endometrio.
As advanced melanoma and endometrial carcinoma is highly resistant to chemotherapy it is important the research focused to the search of therapeutic targets. In the present work, we have investigated the effects of somatostatin analogues (SAs), proteasome inhibitors (PI) such as Bortezomib, the tyrosine kinase receptor inhibitor Sunitinib and the combined therapy of Sunitinib and Bortezomib. This combination has been also tested in endometrial carcinoma. It is observed that melanoma cell lines express various somatostatin receptors. In addition, proteasome inhibitors induce a cell cycle arrest and apoptosis. Those cells presenting activated PDGFRα or VEGFR2 are more sensitive to Sunitinib and this interacts synergistically with Bortezomib. In endometrial carcinoma, Sunitinib induces a cell cycle arrest, apoptosis, inhibits NFκB pathway and interacts synergistically with Bortezomib. The SAs and PI could be useful combined with other agents and the use of Bortezomib and Sunitinib has shown to be effective in certain cases of melanoma and in endometrial carcinoma.
Muñoz, Menéndez Ana Belén. "Resonancia magnética nuclear y marcadores moleculares en el estudio prequirúrgico de pacientes con carcinoma de endometrio. Correlación con el estadio quirúrgico final." Doctoral thesis, Universidad de Cantabria, 2014. http://hdl.handle.net/10803/133095.
Повний текст джерелаIn general , the use of preoperative magnetic imaging is accepted for staging in endometrial carcinoma. However, in our hospital, we have been observing a discrepancy between the results of preoperative MRI and subsequent surgical staging . This has made us wonder if, in our environment, it is a necessary diagnostic test in all our patients for diagnosis prior to surgery , or if , perhaps , we should exclude it from our endometrial cancer staging protocol. We studied the patients with endometrial cancer who had surgery in our department between January 2007 and December 2011, which had undergone preoperative MRI. There was a complete coincidence between the results of the Nuclear Magnetic Resonance preoperative and final surgical stage only in 47.2 % of cases analyzed. The data obtained in the subgroup of type I endometrial carcinomas are much more reasonable, seeing a 63.9 % correct staging , more in line with published studies on the topic, and in any case of this subgroup, staging failure meant a change in the final treatment or prognosis.
Dahmoun, Marju. "Apoptosis, proliferation, and sex steroid receptors in endometrium and endometrial carcinoma." Doctoral thesis, Umeå : Univ, 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-112.
Повний текст джерелаVaskivuo, T. (Tommi). "Regulation of apoptosis in the female reproductive system." Doctoral thesis, University of Oulu, 2002. http://urn.fi/urn:isbn:9514266676.
Повний текст джерелаHAMID, ATIA AKHTAR. "Cyclical Change of hMSH2 Protein Expression in Normal endometrium during the Menstrual Cycle and its Overexpression in Endometrial Hyperplasia and Sporadic Endometrial Carcinoma." Kyoto University, 2002. http://hdl.handle.net/2433/149704.
Повний текст джерела0048
新制・課程博士
博士(医学)
甲第9461号
医博第2474号
新制||医||795(附属図書館)
UT51-2002-G219
京都大学大学院医学研究科外科系器官外科学(婦人科学産科学)専攻
(主査)教授 中畑 龍俊, 教授 丹羽 太貫, 教授 藤井 信吾
学位規則第4条第1項該当
TOZZI, ALESSANDRA. "The unfolded protein response: a link between endometrioid ovarian carcinoma and endometriosis." Doctoral thesis, Università Politecnica delle Marche, 2017. http://hdl.handle.net/11566/245358.
Повний текст джерелаThe present study aims to analyze the activation profile of Unfolded Protein Response (UPR) related genes in endometriod ovarian carcinoma and to assess its possible involvement in the neoplastic transformation from endometriosis. The study was performed using different histological samples: endometrioid carcinoma of the ovary, healthy ovary, endometriosis cysts, eutopic endometrium from patients with endometriosis and healthy endometrium. From all the samples RNA was extracted and cDNA synthesis was performed by reverse transcription. cDNA was used for quantitative gene expression assays, made by Real Time PCR, analyzing genes belonging to the UPR pathway. Samples were divided into three groups: patients with endometriosis (n = 6), healthy patients (n = 6) patients with ovarian endometrioid carcinoma (n = 6). Statistical analysis performed was a t - test, testing the statistical differences, between data means from healthy patients (CTRL) and groups of patients with endometriosis (Ectopic and Eutopic) and patient with endometrioid carcinoma of the ovary (CA). We started analyzing the different expression of UPR pathway in endometrioid ovarian carcinoma compared to healthy ovary and we demonstrated an altered UPR gene expression in patients affected by endometrioid ovarian carcinoma, compared to healthy ovary. As a second step, we decided to analyze the UPR pathway genetic expression in the endometrioid ovarian carcinoma compared to the endometrium of healthy patients and of endometriosis patients. Our study shows a gradual reduction of XBP1 expression in endometriosis, characterized by intense inflammation, and endometrioid ovarian carcinoma, thus strengthening the hypothesis of XBP1 as a marker of neoplastic transformation. Conclusively XBP1s has a high basic expression in healthy endometrium, being a secretive tissue, then gradually decreases in endometriosis and to a higher degree, in ovarian carcinoma. Understanding these mechanisms could represent an important step, for a better definition of cancer pathogenesis, and also in the future, for the development of customized therapies.
Pandey, Vijay. "Secreted oncogenes in endometrial carcinoma." Thesis, University of Auckland, 2010. http://hdl.handle.net/2292/8195.
Повний текст джерелаNgai, Yin-ping. "p21-activated kinases in endometrial carcinoma." Click to view the E-thesis via HKUTO, 2008. http://sunzi.lib.hku.hk/hkuto/record/B40738528.
Повний текст джерела魏燕萍 and Yin-ping Ngai. "p21-activated kinases in endometrial carcinoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2008. http://hub.hku.hk/bib/B40738528.
Повний текст джерелаSaidi, Samir Arif. "A systems biology approach to endometrial carcinoma." Thesis, University of Cambridge, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.612981.
Повний текст джерелаWang, Yue. "Molecular analysis of mitochondrial DNA alterations in endometrial carcinomas." Click to view the E-thesis via HKUTO, 2005. http://sunzi.lib.hku.hk/hkuto/record/B32059127.
Повний текст джерелаLundgren, Caroline. "Endometrial carcinoma : prognostic factors and protein expression profiling /." Stockholm, 2004. http://diss.kib.ki.se/2004/91-7140-002-8/.
Повний текст джерелаLevan, Kristina. "Molecular characterization of type 1 endometrial carcinomas /." Göteborg : Department of Oncology, Institute of Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg, 2009. http://hdl.handle.net/2077/19401.
Повний текст джерелаLiao, Xiaoyun. "Hedgehog signaling pathway and epigenetic studies in ovarian carcinomas and endometrial carcinomas." Click to view the E-thesis via HKUTO, 2008. http://sunzi.lib.hku.hk/hkuto/record/B41290367.
Повний текст джерелаLiao, Xiaoyun, and 廖晓耘. "Hedgehog signaling pathway and epigenetic studies in ovarian carcinomas and endometrial carcinomas." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2008. http://hub.hku.hk/bib/B41290367.
Повний текст джерелаChan, Kwan-yi Queeny, and 陳君怡. "Molecular study of pi-class glutathione-S-transferase in endometrial carcinoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2003. http://hub.hku.hk/bib/B29157717.
Повний текст джерелаWang, Yue, and 王悦. "Molecular analysis of mitochondrial DNA alterations in endometrial carcinomas." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2005. http://hub.hku.hk/bib/B32059127.
Повний текст джерелаBoman, Karin. "Endometrial carcinoma : steroid hormones and receptors in relation to proliferation." Doctoral thesis, Umeå universitet, Onkologi, 1993. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-100588.
Повний текст джерелаDiss. (sammanfattning) Umeå : Umeå universitet, 1993, härtill 5 uppsatser.
digitalisering@umu
Koivisto, Christopher Steven. "Dissecting the Pathogenesis of Type I Endometrial Carcinoma through Mouse Models." The Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu1531995361428894.
Повний текст джерелаWei, Linxuan, Xiaolin Liu, Wenjing Zhang, Yuyan Wei, Yingwei Li, Qing Zhang, Ruifen Dong, et al. "Overexpression and oncogenic function of HMGA2 in endometrial serous carcinogenesis." E-CENTURY PUBLISHING CORP, 2016. http://hdl.handle.net/10150/614759.
Повний текст джерелаAyakannu, Thangesweran. "Investigation of endocannabinoid system signalling pathways and their regulations in endometrial carcinoma." Thesis, University of Leicester, 2017. http://hdl.handle.net/2381/39387.
Повний текст джерелаKurata, Yasuhisa. "Diagnostic performance of MR imaging findings and quantitative values in the differentiation of seromucinous borderline tumour from endometriosis-related malignant ovarian tumour." Kyoto University, 2018. http://hdl.handle.net/2433/232129.
Повний текст джерелаDann, James MacBeth. "Regulation of Vascular Endothelial Growth Factor in endometrial cancer cells by food compounds." Thesis, University of Canterbury. School of Biological Sciences, 2008. http://hdl.handle.net/10092/2113.
Повний текст джерелаKuwahara, Ryo. "A Predictor of Tumor Recurrence in Patients With Endometrial Carcinoma After Complete Resection of the Tumor: The Role of Pretreatment Apparent Diffusion Coefficient." Kyoto University, 2020. http://hdl.handle.net/2433/253483.
Повний текст джерелаWong, Sze-yin Shirley. "Single nucleotide polymorphism in follicle stimulating hormone receptor and the development of endometrial carcinoma." Click to view the E-thesis via HKUTO, 2002. http://sunzi.lib.hku.hk/hkuto/record/B31971349.
Повний текст джерелаWong, Sze-yin Shirley, and 黃思賢. "Single nucleotide polymorphism in follicle stimulating hormone receptor and the development of endometrial carcinoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2002. http://hub.hku.hk/bib/B31971349.
Повний текст джерелаTonon, Ângela Favorito Santarém. "Claudina-3 e Claudina- 4, potenciais marcadores de agressividade no carcinoma endometrial Tipo I /." Botucatu, 2013. http://hdl.handle.net/11449/108608.
Повний текст джерелаCoorientador: Maria Aparecida Custódio Domingues
Banca: Agnaldo Lopes da Silva Filho
Banca: Spergio Mancini Nicolau
Banca: Wagner José Gonçalves
Resumo: O Carcinoma de Endométrio é a neoplasia epitelial maligna que acomete mulheres no pré, pós e peri -menopausa. Segundo diferenças endócrinas, metabólicas, fatores de risco e morfologia é classificado em dois grandes grupos: Tipo I (endometrióide) e Tipo II (não endometrióide). O Tipo I perfaz 90 % dos carcinomas de endométrio e sua patogenia esta ligada a exposição excessiva ao estrógeno. O Tipo II é incomum, com fatores predisponentes menos conhecidos. O sintoma mais relevante do carcinoma de endométrio é o sangramento pós-menopausa. Seu diagnóstico é feito pela comprovação histológica, associada aos exames de imagem e laboratoriais. Seu tratamento é fundamentalmente cirúrgico. O fator prognóstico mais importante é a presença ou ausência de metástase nos linfonodos regionais. Atualmente, buscam-se marcadores biológicos e teciduais que indiquem pior prognóstico. Este trabalho verificou a imunoexpressão da claudina-3 (CLDN3) e claudina-4 (CLDN4) nos carcinomas de endométrio Tipo I e Tipo II, relacionando-as com endométrio proliferativo e atrófico, aspectos clínicos, anatomopatológicos, perfil hormonal, índice de proliferação celular e expressão da p53, na tentativa de estabelecer a importância destas proteínas na progressão e agressividade tumoral e o seu valor prognóstico. Foram estudados 79 casos de carcinoma de endométrio e comparados com 74 endométrios normais. Avaliou-se a imunoexpressão das CLDNs 3 e 4, receptor estrogênico, receptor de progesterona, índice de proliferação celular (Ki67) e p53, pela técnica de imunoistoquímica. Observou-se que o padrão de coloração da membrana para CLDN3 se mostrou difuso nos carcinomas, quando comparado com os endométrios normais que exibiu padrão focal. O número de células marcadas com CLDN3 estava diminuído nos carcinomas Tipo I, porém com intensidade aumentada. Nesta análise foi possível verificar que ...
Abstract: Carcinoma of the Endometrium is a malignant epithelial tumor which affects pre, peri and post-menopausal women. It is classified into two major groups, according to endocrine, metabolic risk factors and morphological differences: Type I (endometrioid) and Type II (non-endometrioid). Type I accounts for 90% of all endometrial carcinomas and its pathogenesis is linked to excessive estrogen exposure. The Type II is less common, with poorly defined predisposing factors. The most important symptom of endometrial carcinoma is postmenopausal bleeding. Diagnosis is achieved through histological evidence, in association with imaging and laboratorial exams. Treatment is primarily surgical. The most important prognostic factor is the presence or absence of metastases in regional lymph nodes. Bio and tissue markers that indicate worse prognosis are the focus of current research. This study examined the immunoexpression of claudin-3 (CLDN3) and claudin-4 (CLDN4) in endometrial carcinomas Type I and Type II, and their relation to proliferative and atrophic endometrium, clinical and pathological features, hormonal status, proliferation index and p53 expression, in an attempt to establish the importance of these proteins in tumor progression and aggressiveness and their prognostic value. Seventy-nine cases of endometrial carcinoma were studied and compared with 74 normal endometria. The immunoexpression of CLDNs 3 and 4, estrogen receptor, progesterone receptor, cell proliferation index (Ki67) and p53 were all evaluated by immunohistochemistry. Observation verified that the pattern of membrane staining for CLDN3 was diffuse in carcinomas compared with normal endometrium which presented a focal pattern. The number of cells stained with CLDN3 was lower in Type I carcinomas, while staining intensity was greater. Analysis verified that 25% of cases with high expression of CLDN4 and Ki-67 developed metastasis, while 33% of cases with greater CLDN4 staining ...
Mestre
De, Leo Antonio <1985>. "Integrated molecular analysis of endometrial carcinoma: translation of biomarker profiles into the clinical practice." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2021. http://amsdottorato.unibo.it/9642/1/de%20leo_antonio_tesi.pdf.
Повний текст джерелаChoma, André. "Etude rétrospective sur les carcinomes de l'endomètre : expérience clinique d'un groupe coopératif alésien." Montpellier 1, 1989. http://www.theses.fr/1989MON11305.
Повний текст джерелаEbeid, Kareem Atef Nassar. "Nanoparticles for targeted treatment of cancer." Diss., University of Iowa, 2018. https://ir.uiowa.edu/etd/6567.
Повний текст джерелаLlobet, Navàs David. "Estudi dels mecanismes moleculars implicats en la sensibilització a l'apoptosi en cèl·lules de carcinoma d'endometri." Doctoral thesis, Universitat de Lleida, 2009. http://hdl.handle.net/10803/8097.
Повний текст джерелаWang, Lin 1967. "A comparative study using endovaginal sonography and magnetic resonance imaging in the staging of endometrial carcinoma /." Thesis, McGill University, 2000. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=32895.
Повний текст джерелаPurpose. (1) To evaluate prospectively the relative accuracy of endovaginal US (including Doppler) and MR imaging using phased array pelvic multicoil in the preoperative staging of endometrial carcinoma with histopathological correlation on the same patient population, (2) To determine whether the addition of contrast-enhanced MR sequences to high resolution fast spinecho (FSE) T2-weighted sequences, can improve the diagnostic accuracy of staging endometrial carcinoma. (Abstract shortened by UMI.)
Garcia, Tiago Selbach. "Avaliação da concordância histológica entre a amostra endometrial pré-operatória e a peça uterina nos carcinomas do endométrio." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2015. http://hdl.handle.net/10183/139987.
Повний текст джерелаBackground: endometrial carcinoma treatment is based on surgical staging, including hysterectomy with bilateral salpingo-oophorectomy and pelvic and paraortic lymphadenectomy. The benefits of systematic lymphadenectomy in all patients have been questioned, since the risk of dissemination in low risk tumors is small and there is no evidence of benefits in its execution. Thereby, researches are looking for ways to determine, by preoperative evaluation, which patient will benefit from full staging and those who can do without the procedure. Objectives: evaluate the agreement between the preoperative endometrial samples and the surgical specimens in endometrial carcinoma, correlating it with characteristics of the samples and patients included, and evaluate the interobserver agreement of the preoperative biopsy. Methods: patients submitted to surgery as primary treatment for endometrial carcinoma at HCPA with a preoperative endometrial sampling were included. Their medical charts were reviewed. The available samples of the preoperative biopsies were recollected for reanalyzes by two pathologists. Inadequate transcriptions of the biopsy report were excluded. Results: we included 166 patients, with a mean age of 64.6 years. Of the biopsies, 118 were endometrioid, 38 were non-endometrioid and the remaining, hyperplasia. The agreement rates were 93.2% for endometrioid tumors and 68.9% for non-endometrioid, with a kappa index of 0.73 for the tumor cell type. The tumor FIGO grade distributed as G1 in 37.1%, G2 in 35.7% and G3 in 27.1%, with an agreement rate of 61.5%, 56% and 78.9%, respectively. The general kappa index for FIGO grading was 0.46. Of the G1 tumors, only 1.9% upgraded to G3, while 16% of the G2 lesions upgraded. There was no statistical difference in the agreement rates of tumor cell type and FIGO grading in function of place of biopsy execution, method of endometrial sampling and biopsy-surgery interval. Biopsies weighing more than 3g had a significantly better agreement in FIGO grading (p=0.040). Samples of 105 were available at HCPA and were reevaluated by 2 pathologists, with a general interobserver agreement 73.3/% (k=0.58) for tumor cell type and 57.9% (k=0.54) for grading. Conclusion: the accuracy of the preoperative biopsy in predicting the definite surgical characteristics it is not ideal. Caution must be taken when using this information to determine the surgical extension, due to the risk of under staging. These low rates of agreement are correlated with the low interobserver agreement. New grading systems and specialists teams are possible ways of improving this issue.
Taylor, Sarah Elizabeth. "Investigation of Protein Phosphatase 2A A-alpha Subunit Mutation as a Disease Driver in High-Grade Endometrial Carcinoma." Case Western Reserve University School of Graduate Studies / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=case1567791544641051.
Повний текст джерелаSandberg, Therese, and Rebecka Fridén. "Utbyte av xylen till Tissue Clear som avparaffineringsmedel vid diagnostik av endometrioid carcinom med DNA-ploidi." Thesis, Hälsohögskolan, Jönköping University, HHJ, Avd. för naturvetenskap och biomedicin, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:hj:diva-48782.
Повний текст джерелаDNA ploidy is used for endometrial cancer diagnosis. It reflects the cell cycle and determines whether the cell population in tumors is diploid or aneuploid. When analyzing paraffin embedded tissues xylene can be used for deparaffinization, whose toxicity impairs the laboratory´s work environment. Its strong and unpleasant smell can cause nausea and dizziness. The aim of this study was to investigate if xylene can be replaced with Tissue Clear, an isoparaffinic hydrocarbon that is less toxic. The study included paraffin embedded human tissues from endometrioid carcinoma (n=20), both diploid (n=15) and aneuploid (n=5), deparaffinized with xylene or Tissue Clear before DNA ploidy was performed. Potential differences between the parameters % CV-diploid, % S-phase, % debris and DI-aneuploid were statistically examined and showed no significant differences. The sample amount in this study might be considered low, though it is relatively high since the analysis is rarely performed routinely. Among these only 25 % were aneuploid. Patients showing aneuploidy is rare and the amount was therefore considered to be sufficient as well. The study shows that deparaffinization with Tissue Clear generates equivalent results as for xylene and can thereby replace xylene regardless if the tissue is diploid or aneuploid.
Lindberg, Mallory E. "THE IMPACT OF E-CADHERIN AND PHOSPHATASE AND TENSIN HOMOLOG ABLATION IN THE UTERUS: THE PROGRESSION OF TYPE I ENDOMETRIAL CARCINOMA." OpenSIUC, 2014. https://opensiuc.lib.siu.edu/theses/1411.
Повний текст джерелаHonkavuori-Toivola, M. (Maria). "The prognostic role of matrix metalloproteinase-2 and -9 and their tissue inhibitor-1 and -2 in endometrial carcinoma." Doctoral thesis, Oulun yliopisto, 2014. http://urn.fi/urn:isbn:9789526204505.
Повний текст джерелаTiivistelmä Kohdunrungon syöpä on yleisin gynekologinen maligniteetti kehittyneissä maissa. Varhaisten oireiden, kuten poikkeavan verisen vuodon, vuoksi kohdunrungon syöpä havaitaan usein varhaisessa vaiheessa, jolloin sen ennuste on hyvä. Taudin käyttäytyminen voi kuitenkin olla moninaista. Viime vuosikymmenten aikana kohdunrungon syöpään sairastuneiden ennuste ei ole merkittävästi parantunut. Vaikuttaisi siltä, että perinteiset ennustetekijät eivät ole riittävän tarkkoja ennustamaan syövän taudinkulkua. Lisäksi liitännäishoidot voivat olla kalliita, ja niihin voi liittyä vakavia haittavaikutuksia. Uusien biologisten ennustetekijöiden löytäminen olisi tärkeää, jotta aggressiivista syöpätyyppiä sairastavat potilaat pystyttäisiin tunnistamaan entistä paremmin, ja hoito kyettäisiin räätälöimään yksilöllisemmin taudinkuvaa vastaavasti. Gelatinaasien (MMP-2 ja MMP-9) sekä niiden kudosinhibiittoreiden (TIMP-1 ja TIMP-2) on havaittu osallistuvan syövän etenemiseen. Tässä tutkimuksessa tarkasteltiin MMP-2:n ja MMP-9:n sekä niiden kudosinhibiittoreiden TIMP-1:n ja TIMP-2:n ilmentymistä ja ennusteellista merkitystä kohdunrungon syövässä. Aineisto käsitti yhteensä 266 primaariseen kohdunrungon syöpään sairastunutta naista. Määritysmenetelminä käytettiin sekä immunohistokemiallista värjäystä parafiiniin valettujen kudosnäytteiden osalta että ELISA-määrityksiä ennen hoitoa otettujen seeruminäytteiden osalta. Syöpäkudoksen runsas MMP-2 -proteiinin ilmentyminen liittyi epäsuotuisaan ennusteeseen, kun taas kasvainkudoksen voimakas TIMP-2 -proteiinin ilmentyminen oli hyvän ennusteen merkki. Lisäksi kasvainkudoksen voimakkaan MMP-2- ja heikon TIMP-2 -proteiinien ilmentymisen yhdistelmän havaittiin liittyvän suurempaan syövästä johtuvaan kuolleisuuteen. MMP-2 -negatiivisten potilaiden eloonjäämisennuste oli paras, TIMP-2 -värjäystuloksesta riippumatta. Seerumin korkea TIMP-1 -pitoisuus oli merkittävä huonontuneen ennusteen merkki. Tutkimuksen tulokset viittaavat siihen, että kasvainkudoksessa esiintyvät MMP-2- ja TIMP-2 -proteiinit samoin kuin seerumin TIMP-1 -pitoisuus voivat ennustaa kohdunrungon syövän kliinistä käyttäytymistä. Kasvainkudoksessa esiintyvä MMP-2 -proteiini vaikuttaisi olevan merkittävin ennusteellinen tekijä, mutta tulosten varmistamiseksi tarvitaan lisää tutkimuksia suuremmilla potilasaineistoilla
Kanopienė, Daiva. "Clinical relevance of studies on microsatellite instability and DNA mismatch repair system protein expression in endometrial carcinomas." Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2014. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2014~D_20141209_111951-10166.
Повний текст джерелаMikrosatelitų nestabilumo tyrimai svarbūs vėžio ligos prognozei vertinti bei parenkant individualų gydymą. Darbo tikslas − ištirti mikrosatelitų nestabilumo dažnį, pobūdį ir klaidingai suporuotų nukleotidų DNR pažaidų taisymo sistemos baltymų raišką sergant gimdos kūno vėžiu ir gautus rezultatus susieti su pacienčių klinikinėmis-patologinėmis charakteristikomis bei jų išgyvenamumu. Į stebėsenos perspektyvinį tyrimą buvo įtrauktos 109 pacientės. Darbo uždaviniai: nustatyti mikrosatelitų nestabilumo dažnį ir pobūdį tarp sergančiųjų gimdos kūno vėžiu, panaudojus Promega Corporation (JAV) sukurtus du žymenų rinkinius (anksčiau sukurtą BAT-25, BAT-26, NR-21, NR-24, MONO-27 ir naująjį BAT-52, BAT-55, BAT-56, BAT-57, BAT-59); palyginti mikrosatelitų nestabilumo dažnį ir pobūdį su pacienčių klinikinėmis-patologinėmis charakteristikomis; ištirti DNR pažaidų taisymo sistemos baltymų (MLH1, PMS2, MSH2, MSH6) raišką gimdos kūno navikuose, kuriuose nustatytas didelio dažnio mikrosatelitų nestabilumas; įvertinti mikrosatelitų nestabilumo įtaką pacienčių išgyvenamumui. Tyrimų rezultatai parodė, kad mikrosatelitų didelio dažnio nestabilumas dvigubai dažniau nustatytas naudojant naująjį žymenų rinkinį, palyginti su anksčiau sukurtu žymenų rinkiniu. Statistiškai reikšminga sąsaja konstatuota tarp mikrosatelitų didelio dažnio nestabilumo arba jo nebuvimo ir naviko diferenciacijos laipsnio bei invazijos į miometriumą gylio. Sergančiųjų išgyvenamumas nebuvo susijęs su mikrosatelitų nestabilumu. ... [toliau žr. visą tekstą]
Appel, Márcia. "CA 125 e p53 no pré-operatório da neoplasia de endométrio e seu valor preditivo para doença linfonodal." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2014. http://hdl.handle.net/10183/97253.
Повний текст джерелаIntroduction: endometrial carcinoma is one of the most common gynecological malignancies in industrialized countries. The treatment of this disease is primarily surgical. According to the International Federation of Gynecology and Obstetrics surgery ideal consists in performing total hysterectomy, bilateral adnexectomy, retroperitoneal lymphadenectomy and peritoneal cytology. However, the systematic lymphadenectomy has been disputed, and should only be performed in a group of patients at high risk of lymphatic spread of the disease. The challenge is to find preoperative markers that may be predictive of the presence of lymph node disease and thus come to be used to determine the necessity of lymphadenectomy. Objectives: to determine whether the positive immunohistochemical expression (IMH) of p53 in diagnostic endometrial sample and, if the value of serum CA 125, obtained during pre-operative, can be effective to predict the presence of lymph node disease. Methods: a cross-sectional study was conducted. The final sample consisted of 111 patients with endometrial carcinoma undergoing hysterectomy with bilateral adnexectomy and lymphadenectomy with or without peritoneal cytology. Ninety two patients had preoperative CA 125 and 73, evaluation of p53. Fifty four patients had both variables in combination. Associations have been established between the value of CA 125 and IMH expression of p53 with lymph node involvement. A ROC curve was constructed to identify the value of CA 125 with better sensitivity (S) and specificity (E) for lymph node disease.
Santos, Nataly Melo dos. "Análise do perfil de expressão e papel fisiopatológico de isoformas da p53 e da osteopontina em linhagens celulares de carcinoma de endométrio." Niterói, 2017. https://app.uff.br/riuff/handle/1/3785.
Повний текст джерелаMade available in DSpace on 2017-06-05T19:10:20Z (GMT). No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Nataly Melo.pdf: 1795665 bytes, checksum: d444f8f78deb979ec897ad76fde8f8cd (MD5)
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro.
Uma série de genes vem sendo estudados por terem sua expressão aberrante em tumores de endométrio. Dentre eles, a osteopontina (OPN) e a p53, os quais são expressos de forma aberrante no carcinoma de endométrio (CE). Tem sido demonstrado que a expressão da OPN é capaz de regular a expressão de p53 e vice-versa. No entanto, ainda não há dados sobre as isoformas destes produtos gênicos e suas possíveis relações no CE. Este trabalho teve por objetivo avaliar o perfil de expressão e o potencial papel fisiopatológico das isoformas da OPN e da p53 em distintas linhagens celulares de endométrio. A expressão destes alvos foi avaliada por PCR em tempo real, imunoblot e imunofluorescência. Observamos que a OPNa é a isoforma predominante dentre as três isoformas, tanto em linhagens tumorais quanto não tumorais de endométrio. No entanto, apenas a isoforma OPNc apresenta expressão diferencial entre linhagens tumorais e uma não tumoral. De forma similar, todas as isoformas de p53 também são expressas nestas linhagens investigadas, sendo a p53 completa a isoforma predominante em linhagens tumorais e a Δ40p53 a segunda mais expressa, em especial em linhagens representativas de tumores do Tipo I. A variante Δ40p53 apresenta expressão predominante em linhagens celulares não tumorais de endométrio. Em conjunto, estes dados evidenciam correlação entre a expressão predominante da isoforma OPNa e a variante completa da p53, com padrões específicos de expressão da OPNc e da Δ40p53, de acordo as linhagens analisadas. Estes achados abrem perspectivas da potencial aplicação de isoformas variantes da OPN e de p53 enquanto biomarcadores no diagnóstico diferencial e também para avaliação prognóstica em tumores de endométrio.
Several genes have been studied by being overexpressed in endometrial tumors. Among them, osteopontin (OPN) and p53, which are overexpressed in endometrial carcinoma (EC). It has been demonstrated that the expression of OPN can regulate the expression of p53 and vice-versa. However, data is lacking regarding these gene products and their putative associations in EC. This work aims to evaluate the expression profile and the potential physiopathological roles of OPN and p53 isoforms in distinct endometrial cell lines.The expression of these gene targets has been evaluated here by real time PCR, immunoblot and immunofluorescense. We observed that OPNa is the predominant isoform among those three tested, both in tumor and non-tumoral cell lines. However, only OPNc isoform is differentially expressed between tumor and non-tumoral cell lines. Similarly, all p53 isoforms are expressed in these tested cell lines, being the full lenght p53 the predominant isoform in tumor cell lines, while Δ40p53 is the second variant in expression levels, especially in cell lines that are representative of Type I tumors. The Δ40p53 variant has predominat expression in non-tumoral cell lines. As a whole, these data evidence correlation between the predominant expression of OPNa and the full lenght p53 variant, with specific expression patterns observed for OPNc and Δ40p53, according to analyzed cell lines. These data open perspectives of the potential use of OPN and p53 isoform variants as biomarkers for differential diagnosis and prognostic evaluation in endometrial tumors.
Reinhold, Caroline. "The use of endovaginal sonography and Doppler ultrasound in the detection of endometrial carcinoma in women presenting with postmenopausal bleeding." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk2/ftp03/MQ64436.pdf.
Повний текст джерелаSilveira, Razyane Audibert. "Avaliação da concordância da expressão imuno-histoquímica da proteína p53 entre a amostra endometrial pré-operatória e a peça uterina nos carcinomas de endométrio." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2017. http://hdl.handle.net/10183/179704.
Повний текст джерелаObjective: To evaluate the agreement of the immunohistochemical (IMH) expression of the p53 protein (p53) in preoperative endometrial tissues and in surgical specimens obtained during hysterectomy, to determine the association of this agreement with factors such as histological type, tumor grade and stage and to evaluate interobserver agreement for the expression and intensity of p53 between the diagnostic biopsy and the surgical specimen. Methods: Retrospective cross-sectional study. Patients with endometrial carcinoma who submitted to endometrial biopsy and primary surgical treatment at the HCPA Genital Oncology Unit were included. The slides were assessed by two pathologists. The percentage of p53 expression was evaluated and categorized into one of three groups (<10%, 10-50% and >50%). The intensity was evaluated as weak, medium or strong. The agreement was assessed by the weighted Kappa coefficient. Results: 72 patients with a mean age of 65.5 years were included. The percentage of p53 expression between the biopsy and the surgical specimen presented an agreement rate of 70.8%, with a weighted Kappa index of 0.64. The intensity of expression had an agreement rate of 69.4% with a weighted Kappa of 0.65. When evaluated according to histological type and tumor grade, the agreement for p53 expression showed weighted Kappa indexes of 0.64 and 0.72 in non-endometrioid and G3 carcinomas, respectively (p<0.001). With respect to the biopsy, the interobserver agreement for the expression and intensity of p53 had weighted Kappa indexes of 0.77 and 0.75, respectively. With respect to the surgical specimen, the weighted Kappa indexes were 0.85 and 0.88 for expression and intensity, respectively. 11 Conclusions: This study found good agreement rates for the expression and intensity of p53 IMH expression between the endometrial biopsy specimen and the surgical specimen, which may be useful in a preoperative setting for the selection of patients who are candidates for more extensive surgery, especially when anatomopathological biopsy data are insufficient for such a decision.
Rush, Craig M. "Characterization of MAX and FOXA2 mutations unique to endometrial cancer." The Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu1542204873523922.
Повний текст джерелаNanbu, Kanako. "Expression of heat shock proteins HSP70 and HSP90 in endometrial carcinomas : correlation with clinicopathology, sex steroid receptor status, and p53 protein expression." Kyoto University, 1999. http://hdl.handle.net/2433/181231.
Повний текст джерелаButler, Stephen Andrew. "Investigations into the role of human chorionic gonadotrophin beta as a new growth factor in carcinoma of the bladder, cervix and endometrium : novel structures, functions and treatments." Thesis, Queen Mary, University of London, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.249591.
Повний текст джерела